ArticlePharmacogenetics and genomics2008
Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans.
Article in Pharmacogenetics and genomics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A resource for integrated genomic analysis of the human liver.Scientific reports · 2022Pooled it
- Genetic polymorphisms of pharmacogenomic VIP variants in the Lisu population of southwestern China: A cohort study.Medicine · 2018Observational
- Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines.The pharmacogenomics journal · 2017Article
- The limits of genome-wide methods for pharmacogenomic testing.Pharmacogenetics and genomics · 2012Article
- An integrative functional genomics approach for discovering biomarkers in schizophrenia.Briefings in functional genomics · 2011Review
- Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype.Pharmacogenetics and genomics · 2010Article
- Mapping transcription mechanisms from multimodal genomic data.BMC bioinformatics · 2010Article
- Different effects of the probe summarization algorithms PLIER and RMA on high-level analysis of Affymetrix exon arrays.BMC bioinformatics · 2010Article
- Modeling expression quantitative trait loci in data combining ethnic populations.BMC bioinformatics · 2010Article
- Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2010Article
- Pharmacogenomic discovery using cell-based models.Pharmacological reviews · 2009Review
- Genome-wide analysis of immune activation in human T and B cells reveals distinct classes of alternatively spliced genes.PloS one · 2009Article
- Expression quantitative trait loci detected in cell lines are often present in primary tissues.Human molecular genetics · 2009Article
- Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.Journal of translational medicine · 2009Article
- Population-specific GSTM1 copy number variation.Human molecular genetics · 2009Article
- Use of cell lines in the investigation of pharmacogenetic loci.Current pharmaceutical design · 2009Review
- FstSNP-HapMap3: a database of SNPs with high population differentiation for HapMap3.Bioinformation · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThe very important pharmacogenes (VIPs) were selected by Pharmacogenetic Research Network (National Institutes of Health-PGRN) owing to their significant effects on drug treatment both at the pharmacokinetic and pharmacodynamic levels. Our objective was to identify single nucleotide polymorphisms (SNPs) that potentially affected the expression of these genes or potential SNP-gene interactions involved to improve our understanding of genetic effects on drug therapy. BASIC
methodsGene expression was evaluated in 176 International HapMap lymphoblastoid cell lines derived from CEU (CEPH, Utah residents with ancestry from northern and western Europe; n=87) and YRI (Yoruba in Ibadan, Nigeria; n=89) using Affymetrix GeneChip Human Exon 1.0 ST arrays (Affymetrix Laboratory, Affymetrix Inc., Santa Clara, California, USA) with interrogation of greater than 17,000 human genes. Genome-wide association was performed between over two million publicly available HapMap SNPs and gene expression. MAIN
resultsThe expression of two PGRN-VIPs (GSTT1 and GSTM1) are significantly associated with SNPs within 2.5 Mb of the genes; whereas the expression of three and ten PGRN-VIPs are significantly associated with distant-acting SNPs in CEU and YRI, respectively. In addition, three and four PGRN-VIPs harbor SNPs that are distantly associated with other gene expressions in CEU and YRI, respectively. PRINCIPAL
conclusionUsing this information, one may identify genetic variants that are significantly associated with the expression of any set of genes of interest; or evaluate potential gene-gene interaction through SNP expression relationships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.